混合型肝细胞-胆管癌的诊疗进展

摘要/Abstract

摘要： 混合型肝细胞-胆管癌是一种罕见的原发性肝癌,其兼具肝细胞癌和肝内胆管癌特点。而这一特性也导致其难于与肝细胞癌和肝内胆管癌区分。同时混合型肝细胞-胆管癌的预后差,对相关治疗的反应也有别于肝细胞癌和肝内胆管癌,严重危害着患者健康。因此,本文总结了近年来混合型肝细胞-胆管癌诊断和治疗上的最新研究进展,希望能为临床上混合型肝细胞-胆管癌的诊疗提供参考。

关键词: 混合型肝细胞-胆管癌, 肝细胞癌, 肝内胆管癌, 诊断, 治疗

殷霖霖, 赵思, 张秀华, 季国忠. 混合型肝细胞-胆管癌的诊疗进展[J]. 肝脏, 2021, 26(7): 720-723.

[1] Stavraka C,Rush H,Ross P. Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions. J Hepatocell Carcinoma,2019,6:11-21.
[2] Zhao Q,Yu W,Lu X, et al. Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study. Chin J Cancer,2016,35:82.
[3] Kim T,Kim H,Joo I, et al. Combined Hepatocellular-Cholangiocarcinoma: Changes in the 2019 World Health Organization Histological Classification System and Potential Impact on Imaging-Based Diagnosis. Korean J Radiol,2020,21:1115-1125.
[4] Schizas D,Mastoraki A,Routsi E, et al. Combined hepatocellular-cholangiocarcinoma: An update on epidemiology, classification, diagnosis and management. Hepatobiliary Pancreat Dis Int,2020,19:515-523.
[5] Zhang H,Yu X,Xu J, et al. Combined hepatocellular-cholangiocarcinoma: An analysis of clinicopathological characteristics after surgery. Medicine,2019,98:e17102.
[6] Wakizaka K,Yokoo H,Kamiyama T, et al. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers. J Gastroenterol Hepatol,2019,34:1074-1080.
[7] Sagrini E,Iavarone M,Stefanini F, et al. Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma. United European Gastroenterol J,2019,7:69-77.
[8] Sammon J,Fischer S,Menezes R, et al. MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma. Cancer Imaging,2018,18:8.
[9] Wu C,Yong C,Liew E, et al. Combined Hepatocellular Carcinoma and Cholangiocarcinoma:Diagnosis and Prognosis After Resection or Transplantation. Transplant Proc,2016,48:1100-1104.
[10] Yang J,Zhang Y,Li J, et al. Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma. World J Gastroenterol,2020,26:7325-7337.
[11] Jiang H,Song B,Qin Y, et al. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. Eur Radiol,2020,
[12] Liu X,Khalvati F,Namdar K, et al. Can machine learning radiomics provide pre-operative differentiation of combined hepatocellular cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma to inform optimal treatment planning? Eur Radiol,2021,31:244-255.
[13] Ishii T,Ito T,Sumiyoshi S, et al. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma. World J Surg Oncol,2020,18:319.
[14] Zhou Y,Sui C,Zhang X, et al. Influence of cirrhosis on long-term prognosis after surgery in patients with combined hepatocellular-cholangiocarcinoma. BMC Gastroenterol,2017,17:25.
[15] Tao C,Liu W,Jin L, et al. Surgical Treatment of Combined Hepatocellular-Cholangiocarcinoma is as Effective in Elderly Patients as it is in Younger Patients: A Propensity Score Matching Analysis. J Cancer,2018,9:1106-1112.
[16] Jaradat D,Bagias G,Lorf T, et al. Liver transplantation for combined hepatocellular-cholangiocarcinoma: Outcomes and prognostic factors for mortality. A multicenter analysis. Clin Transplant,2021,35:e14094.
[17] Antwi S,Habboush Y,Chase L, et al. Response to Loco-Regional Therapy Predicts Outcomes After Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma. Ann Hepatol,2018,17:969-979.
[18] Wu D,Shen Z,Zhang Y, et al. Effect of liver transplantation in combined hepatocellular and cholangiocellular carcinoma: a case series. BMC cancer,2015,15:232.
[19] Lee J,Chung G,Yu S, et al. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol,2011,45:69-75.
[20] Badar W,Van Ha T,Zangan S, et al. Yttrium-90 Radioembolization Therapy for Combined Hepatocellular and Cholangiocarcinoma. Gastrointest Tumors,2020,7:144-150.
[21] Chan L,Sze D,Poultsides G, et al. Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma. Cardiovasc Intervent Radiol,2017,40:1383-1391.
[22] Kim J,Yoon H,Ko G, et al. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology,2010,255:270-277.
[23] Na S,Choi G,Lee H, et al. The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection. PLoS One,2018,13:e0198138.
[24] Park S,Lee S,Yu E, et al. Combined hepatocellular-cholangiocarcinoma: Gadoxetic acid-enhanced MRI findings correlated with pathologic features and prognosis. J Magn Reson Imaging,2017,46:267-280.
[25] Fowler K,Saad N,Brunt E, et al. Biphenotypic Primary Liver Carcinomas: Assessing Outcomes of Hepatic Directed Therapy. Ann Surg Oncol,2015,22:4130-4137.
[26] Raevskaya O,Appelman H,Razumilava N. A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma. Curr Hepatol Rep,2020,19:478-485.
[27] Kim E,Yoo C,Kang H, et al. Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma. Liver Int,2021.
[28] Kobayashi S,Terashima T,Shiba S, et al. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Sci,2018,109:2549-2557.
[29] Trikalinos N,Zhou A,Doyle M, et al. Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience. J Natl Compr Canc Netw,2018,16:1193-1199.
[30] Rogers J,Bolonesi R,Rashid A, et al. Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy. J Gastrointest Oncol,2017,8:347-351.
[31] Salimon M,Prieux-Klotz C,Tougeron D, et al. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. Br J Cancer,2018,118:325-330.
[32] Liu Z,Lian B,Dong Q, et al. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity. Biochim Biophys Acta Mol Basis Dis,2018,1864:2360-2368.

混合型肝细胞-胆管癌的诊疗进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	马琳, 贾继东. 肝硬化患者营养不良、肌少症和衰弱的临床研究进展[J]. 肝脏, 2021, 26(7): 717-720.
[2]	聂伟杰, 刘家旗, 张锦, 孟存英. ATLI患者遗传易感性及新型生物标志物的研究进展[J]. 肝脏, 2021, 26(7): 807-810.
[3]	黄晓铨, 吴玲, 姜思雨, 李锋, 陈世耀. 丙型肝炎持续病毒应答与肝硬化食管胃静脉曲张患者内镜治疗后再出血的相关性[J]. 肝脏, 2021, 26(6): 597-601.
[4]	段兴刚, 刘立, 刘良婷, 王应甜, 范群雄. 慢性乙型肝炎患者停药导致肝衰竭发生的特征及影响预后的相关因素分析[J]. 肝脏, 2021, 26(6): 617-620.
[5]	邸亮, 赵晓飞, 丁兢. 微血管侵犯对肝细胞癌根治性切除术后复发影响因素分析[J]. 肝脏, 2021, 26(6): 625-627.
[6]	唐改香, 李娅, 张旭. 血清miR-221与催乳素水平对老年非酒精性脂肪性肝病的早期诊断价值研究[J]. 肝脏, 2021, 26(6): 670-673.
[7]	付豪爽, 赵爽, 谢青. 肠道菌群促进肝癌发生的机制及其临床应用[J]. 肝脏, 2021, 26(6): 696-700.
[8]	梁书菀. 肝癌合并门静脉癌栓微创治疗的进展分析[J]. 肝脏, 2021, 26(6): 703-705.
[9]	陈柳汛, 刘旭东, 张杨宇博, 郑辉, 梅浙川. 免疫检查点在肝细胞癌免疫逃逸中的作用研究进展[J]. 肝脏, 2021, 26(6): 706-708.
[10]	杨雪, 陆观珠, 杜成坎, 王博成, 许洁, 包玉洁. G-test在肝细胞癌筛查中的诊断价值[J]. 肝脏, 2021, 26(5): 518-521.
[11]	何春梅, 莫之婧. 基于生物信息学分析鉴定肝细胞癌预后生物标志物[J]. 肝脏, 2021, 26(5): 522-526.
[12]	吉晓妹, 邵春燕, 吉浩明, 顾春燕. 人血白蛋白序贯治疗对原发性肝癌合并肝硬化患者射频消融术后肝功能和预后的影响[J]. 肝脏, 2021, 26(5): 534-537.
[13]	田颖颖, 丁洁, 徐毅明. FibroScan评价ALT升高慢性乙型肝炎患者抗病毒疗效价值[J]. 肝脏, 2021, 26(4): 381-383.
[14]	苏丹, 张伟伟. 非HBV和HCV相关性肝细胞癌患者临床特征及预后影响因素分析[J]. 肝脏, 2021, 26(4): 384-387.
[15]	张彬彬, 郁皓, 曹斐, 吴晓霞, 单永锋, 王昊楠, 刘慧. 长链非编码RNA CCAT1可作为肝细胞癌血浆标志物并预测其治疗效果[J]. 肝脏, 2021, 26(4): 392-394.